CLYYF (Celyad Oncology) Stock Based Compensation: $0.14 Mil (TTM As of Dec. 2025)


CLYYF Celyad Oncology SA CLYYF
13 GF Score
Price $0.25
GF Value $0.46
! 6 Warning Signs
View Full Analysis

What is Celyad Oncology Stock Based Compensation?

Celyad Oncology CLYYF 13 Stock Based Compensation is $0.14 Mil as of Dec. 2025. GuruFocus rates CLYYF with a GF Score™ of 13/100 and a GF Value™ of $0.46. The stock has 6 warning signs investors should review.

Celyad Oncology's Stock Based Compensation for the six months ended in Dec. 2025 was $0.07 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was $0.14 Mil.

Celyad Oncology Stock Based Compensation Related Terms

Celyad Oncology Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Celyad Oncology's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celyad Oncology Stock Based Compensation Chart

Celyad Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.45 1.72 1.02 0.04 0.14

Celyad Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.01 0.03 0.07 0.07
CLYYF
13GF Score
Celyad Oncology SA CLYYF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celyad Oncology Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.14 Mil.

What does a Stock Based Compensation of $0.14 Mil mean?
Celyad Oncology (CLYYF) has a Stock Based Compensation of $0.14 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Celyad Oncology and its competitors.
Is Celyad Oncology's Stock Based Compensation too high?
Celyad Oncology's current Stock Based Compensation is $0.14 Mil. Overall, Celyad Oncology has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celyad Oncology's Stock Based Compensation compare to VRTX and REGN?
Celyad Oncology's Stock Based Compensation of $0.14 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Celyad Oncology and its competitors. Celyad Oncology's current Stock Based Compensation is $0.14 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celyad Oncology stock overvalued right now?
Celyad Oncology (CLYYF) has a current Stock Based Compensation of $0.14 Mil. The stock's GF Value™ is $0.46, compared to a current price of $0.25 — trading 45.7% below its estimated fair value. The current Stock Based Compensation is $0.14 Mil. Celyad Oncology's overall GF Score™ is 13/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Celyad Oncology (CLYYF), the current Stock Based Compensation is $0.14 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celyad Oncology (CLYYF) Overvalued in 2026?

Based on GuruFocus' analysis, Celyad Oncology stock appears to be undervalued. The current stock price of $0.25 is trading 45.7% below its estimated GF Value™ of $0.46.

Key valuation signals for CLYYF:

  • Stock Based Compensation: $0.14 Mil
  • GF Value™: $0.46 vs. price of $0.25 (45.7% below fair value)
  • GF Score™: 13/100 with 6 warning signs

No single metric tells the full story. See the CLYYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celyad Oncology Business Description

Address Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
13GF Score

Get the complete analysis for CLYYF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.46
GF Value